Chungwoo 50% Dextrose Injection

Adult administration

20 to 500 mL is administered intravenously per dose. The rate of intravenous administration should not exceed 0.5 g/kg of glucose per hour. Use an appropriate amount for dissolving or diluting the injection. Adjust as necessary according to age and symptoms.

Caution should be exercised when cutting this medication as glass fragments may enter when using the ampoule injection, especially when administered to children or the elderly. The glucose included in this medication may increase the consumption of thiamine (Vitamin B₁) during intravenous administration, potentially leading to fatal deficiency, so caution is necessary. This medication should not be administered to patients with storage dehydration, excessive fluids, hyperglycemia, acidosis, hypokalemia, hyperosmolar coma, glucose intolerance, anuria, or hepatic coma. Additionally, this medication in hypertonic form should not be used in patients with spinal cord hemorrhage or intracranial hemorrhage, and caution should be taken in severely dehydrated patients as it may worsen hyperosmolar conditions. In patients with a tendency for potassium, phosphate, or magnesium deficiency, or those with hyponatremia, diabetes insipidus, renal failure, heart failure, severe malnutrition, thiamine deficiency, sepsis, severe trauma, shock, chronic uremia, or diabetes, it should be administered cautiously. Rapid administration of this medication in large quantities can lead to electrolyte loss, and exceeding the recommended dose may increase bilirubin and lactate levels, necessitating caution. Adverse reactions may include hypokalemia, hypertonic coma, acidosis, dehydration, hyperosmolarity, polyuria, fluid overload, congestion, pulmonary edema, phlebitis, thrombosis, and local pain at the injection site. Prolonged administration may affect insulin production, so insulin should be given together if necessary, and blood glucose and electrolyte levels should be regularly monitored while considering fluid balance. During pregnancy, the potential risk to the fetus necessitates use only when the therapeutic benefits outweigh the risks, and administration during labor may lead to hyperglycemia and hypoglycemia in both the mother and newborn, requiring careful judgment. In children and newborns, their fluid and electrolyte regulation capabilities are immature, so blood glucose and electrolyte levels should be closely monitored, particularly in preterm or low-birth-weight infants as the risk of intracranial hemorrhage may increase. Elderly patients may have reduced body function, so administration should be done with extra caution. Overdosage may lead to hyperglycemia and diabetes, which may necessitate insulin administration. Subcutaneous injections may cause circulatory failure due to electrolyte shifts in plasma and should be avoided due to significant local irritation; any remaining medication after opening should be disposed of immediately. When administering injections, precautions against infection should be taken, and the solution should be warmed to body temperature during cold weather. A sudden stop after administering concentrated solutions may cause hypoglycemia, so gradual adjustments are required, and interactions and adverse reaction possibilities should be thoroughly considered when administering with other medications. To prevent air embolism, avoid injecting air into the container and refrain from continuous connected administration.

Mild side effects

• Hypokalemia
• acidosis
• dehydration
• hyperosmolarity
• polyuria
• fluid or solute overload
• electrolyte imbalance
• congestion
• pulmonary edema
• hyperglycemia

This medication should be stored in a sealed container to protect it from air and moisture. This will help maintain the efficacy of the medication and prevent deterioration.

Appearance

Colorless and transparent solution contained in a multilayer film plastic container

Package unit

50 mL, 100 mL, 500 mL